Faron H1'25 preview: The company is preparing for a decisive trial phase
26 augusti, 10:02
26 augusti, 10:02
During the period, Faron has updated the results of the Phase I/II blood cancer study BEXMAB. The study is now in its final stages, and we believe the results will support the implementation of its final, crucial phase.
26 augusti, 10:02
During the period, Faron has updated the results of the Phase I/II blood cancer study BEXMAB. The study is now in its final stages, and we believe the results will support the implementation of its final, crucial phase.
Nvidia-rapporten
Analyser
PPM-upphandlingen
Nvidia-rapporten
Analyser
PPM-upphandlingen
1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 643,74